Patents by Inventor Louis A. Tartaglia
Louis A. Tartaglia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220033787Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.Type: ApplicationFiled: October 6, 2021Publication date: February 3, 2022Inventors: Natarajan SETHURAMAN, Jason RUTH, Louis A. TARTAGLIA, Dehua PEI, Ziqing QIAN
-
Patent number: 9845339Abstract: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to a-melanocortin stimulating hormone (a-MSH).Type: GrantFiled: December 28, 2012Date of Patent: December 19, 2017Assignee: RHYTHM PHARMACEUTICALS, INC.Inventors: Louis A. Tartaglia, Bart Henderson
-
Publication number: 20140329743Abstract: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to a-melanocortin stimulating hormone (a-MSH).Type: ApplicationFiled: December 28, 2012Publication date: November 6, 2014Inventors: Louis A. Tartaglia, Bart Henderson
-
Patent number: 7547515Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: August 11, 2005Date of Patent: June 16, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White
-
Publication number: 20080107650Abstract: A method for treating an inflammatory disease of the digestive tract, for example inflammatory bowel disease, in a subject comprises administering to the subject a therapeutically effective amount of a compound selected from the group consisting of (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino]-4-methylpentanoic acid, pharmaceutically acceptable salts thereof and prodrugs thereof.Type: ApplicationFiled: September 7, 2007Publication date: May 8, 2008Applicant: Gene Logic Inc.Inventors: Louis Tartaglia, Thomas Barnes, Robert Coopersmith, Scott Malstrom, David White, Dominic Picarella
-
Publication number: 20070077205Abstract: The present invention provides methods of using non-invasive imaging technologies to monitor the effects of potential therapeutic compounds on gene expression in non-human living animals. This invention also provides methods to analyze perturbation in biochemical pathways and physiological functions associated with disease (e.g., a cancer, cardiovascular disease, degenerative nervous system disease, osteoporosis, disease related to body weight regulation, toxicity, and any other disease condition related to abnormal gene expression) using the non-invasive imaging technologies to monitor alterations in gene expression in non-human living animals.Type: ApplicationFiled: October 10, 2006Publication date: April 5, 2007Inventors: Louis Tartaglia, Alain Stricker-Krongrad
-
Patent number: 7033772Abstract: A family of fatty acid transport proteins (FATPs) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: GrantFiled: September 23, 1999Date of Patent: April 25, 2006Assignees: Millennium Pharmaceuticals, Inc., Whitehead Institute for Biomedical ResearchInventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Publication number: 20060029964Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: ApplicationFiled: August 11, 2005Publication date: February 9, 2006Inventors: Louis Tartaglia, Robert Tepper, Janice Culpepper, David White
-
Patent number: 6977240Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: September 10, 2001Date of Patent: December 20, 2005Assignee: Millenium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White
-
Patent number: 6933115Abstract: The invention concerns the human gene encoding GLUTX, a glucose transporter. GLUTX nucleic acid and polypeptides, as well as molecules which increase or decrease expression or activity of GLUTX, are useful in the diagnosis and treatment of disorders associated with aberrant hexose transport.Type: GrantFiled: October 18, 2001Date of Patent: August 23, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Xun Weng
-
Publication number: 20030232363Abstract: A family of fatty acid transport proteins (FATPs) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: ApplicationFiled: April 1, 2003Publication date: December 18, 2003Inventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Patent number: 6548269Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: April 26, 1996Date of Patent: April 15, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper
-
Publication number: 20030053951Abstract: The present invention provides methods of using non-invasive imaging technologies to monitor the effects of potential therapeutic compounds on gene expression in non-human living animals. This invention also provides methods to analyze perturbation in biochemical pathways and physiological functions associated with disease (e.g. a cancer, cardiovascular disease, degenerative nervous system disease, osteoporosis, disease related to body weight regulation, toxicity, and any other disease condition related to abnormal gene expression) using the non-invasive imaging technologies to monitor alterations in gene expression in non-human living animals.Type: ApplicationFiled: July 26, 2002Publication date: March 20, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Alain Stricker-Krongrad
-
Patent number: 6506877Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: December 28, 1995Date of Patent: January 14, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Louis A Tartaglia, Robert I Tepper, Janice A Culpepper
-
Publication number: 20020182676Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: ApplicationFiled: February 19, 2002Publication date: December 5, 2002Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White
-
Patent number: 6482927Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: September 3, 1996Date of Patent: November 19, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White
-
Publication number: 20020164578Abstract: The invention concerns the human gene encoding GLUTX, a glucose transporter. GLUTX nucleic acid and polypeptides, as well as molecules which increase or decrease expression or activity of GLUTX, are useful in the diagnosis and treatment of disorders associated with aberrant hexose transport.Type: ApplicationFiled: October 18, 2001Publication date: November 7, 2002Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporationInventors: Louis A. Tartaglia, Xun Weng
-
Publication number: 20020119517Abstract: Six genes whose expression is induced by leptin are disclosed (LIG46; LIG56; Tgtp, encoding a T cell-specific GTP-binding protein; LRG-47, encoding an interferon (IFN) inducible protein; RC10-II, encoding a subunit of a 20S brain proteasome; and Stra13, encoding a retinoic acid inducible protein). These six leptin-inducible genes and the proteins they encode represent targets for the development of therapeutic agents for use in modulating body weight. For example, agents that alter the expression or activity of one or more of the leptin-induced proteins can be used to modulate body weight. Such agents can be identified using cellular, in vitro, or in vivo assays which monitor the expression or activity of one or more of the six leptin-induced proteins. Potentially useful therapeutic agents can also be identified through the use of assays designed to identify agents that bind to one of the leptin-induced proteins.Type: ApplicationFiled: March 12, 2001Publication date: August 29, 2002Applicant: Millennium Pharmaceuticals, Inc., Delaware corporationInventors: David White, Jianghong Zhou, Louis A. Tartaglia
-
Patent number: 6403552Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: June 9, 1998Date of Patent: June 11, 2002Assignee: Millenium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White
-
Patent number: 6395498Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.Type: GrantFiled: May 28, 1997Date of Patent: May 28, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White